Qualitative or quantitative defects of fukutin

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:207122
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Qualitative or quantitative defects of fukutin refer to a group of rare genetic disorders caused by mutations in the FKTN gene, which encodes the protein fukutin. Fukutin plays a critical role in the glycosylation of alpha-dystroglycan, a protein essential for maintaining the structural integrity of muscle fibers and proper brain development. Defects in fukutin lead to a spectrum of conditions collectively classified as dystroglycanopathies, most notably Fukuyama congenital muscular dystrophy (FCMD), as well as milder limb-girdle muscular dystrophy type 2M (LGMD R13) and more severe Walker-Warburg syndrome or muscle-eye-brain disease phenotypes. These conditions primarily affect the skeletal muscles, the brain, and the eyes. Key clinical features include progressive muscular weakness and wasting, intellectual disability, seizures, structural brain abnormalities (such as cobblestone lissencephaly and cerebellar cysts), and ocular abnormalities including retinal detachment and myopia. In the most severe forms, such as Walker-Warburg syndrome, affected infants present at birth with profound hypotonia, severe brain malformations, and eye defects, often with a significantly shortened lifespan. Fukuyama congenital muscular dystrophy, the most common form in Japan, typically presents in early infancy with generalized hypotonia, poor feeding, weak cry, and delayed motor milestones. Most affected children never achieve independent ambulation. There is currently no cure for fukutin-related dystroglycanopathies. Treatment is supportive and multidisciplinary, involving physical therapy to maintain mobility, management of seizures with antiepileptic medications, respiratory support as needed, nutritional support, and ophthalmologic and cardiac monitoring. Orthopedic interventions may be required for contractures and scoliosis. Research into gene therapy and pharmacological approaches to restore alpha-dystroglycan glycosylation is ongoing but remains experimental.

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Qualitative or quantitative defects of fukutin.

View clinical trials →

No actively recruiting trials found for Qualitative or quantitative defects of fukutin at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Qualitative or quantitative defects of fukutin community →

No specialists are currently listed for Qualitative or quantitative defects of fukutin.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Qualitative or quantitative defects of fukutin.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Qualitative or quantitative defects of fukutinForum →

No community posts yet. Be the first to share your experience with Qualitative or quantitative defects of fukutin.

Start the conversation →

Latest news about Qualitative or quantitative defects of fukutin

No recent news articles for Qualitative or quantitative defects of fukutin.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Qualitative or quantitative defects of fukutin

What is Qualitative or quantitative defects of fukutin?

Qualitative or quantitative defects of fukutin refer to a group of rare genetic disorders caused by mutations in the FKTN gene, which encodes the protein fukutin. Fukutin plays a critical role in the glycosylation of alpha-dystroglycan, a protein essential for maintaining the structural integrity of muscle fibers and proper brain development. Defects in fukutin lead to a spectrum of conditions collectively classified as dystroglycanopathies, most notably Fukuyama congenital muscular dystrophy (FCMD), as well as milder limb-girdle muscular dystrophy type 2M (LGMD R13) and more severe Walker-War

How is Qualitative or quantitative defects of fukutin inherited?

Qualitative or quantitative defects of fukutin follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.